This clinical trial is for men and women who have advanced cancer that may have spread locally or to other parts of the body and is known to have a mutation in a member of the RAS gene family. RAS genes make proteins inside cells that control cell growth and cell survival, and cancers with a mutated RAS gene often grow and spread more quickly and are harder to treat.
   

The purpose of this study is to test the safety of the study drug, AAVrh.10hFXN, which is an adeno-associated virus serotype rh10 gene transfer vector and see what effects it has to treat the cardiomyopathy associated with Friedreich’s ataxia (FA). The study also aims to find the highest dose of the study drug that can be given without causing severe side effects.

AAVrh.10hFXN is considered experimental, which means it has not yet been approved by the U.S. Food and Drug Administration (FDA).

This clinical trial is for men and women with acute myeloid leukemia (AML) whose cancer has been treated before and has either recurred or did not respond to prior therapy.   

This is one of the first-in-human studies to try to understand how an investigational drug called BP1002 works in the human body and if BP1002 could help cancer patients in the future. Investigational means that BP1002 has not yet been approved by the U.S. Food and Drug Administration (FDA).

Cancers behave differently in different patients; thus, not all therapies will work for everyone. By identifying biological pathways and specific genetic alterations in different cancers, patient treatments can be better tailored, resulting in a personalized approach to treatment.

The purpose of this study is to assess serum testosterone levels after administration of clomiphene citrate (CC) in men with low serum testosterone.

Clomiphene citrate is approved by the U.S. Food and Drug Administration (FDA) to treat some types of infertility in women and is sometimes prescribed off-label for treatment of low testosterone in men. Clomiphene citrate is not FDA approved for this purpose.

This study will test the effect of the oral medication, escitalopram, on male fertility in comparison to a placebo (pills with no study drug). Escitalopram is approved by the U.S. Food and Drug Administration (FDA) and is a commonly prescribed anti-depressant among men of reproductive age. Escitalopram is thought to have negative effects on male fertility but has never been assessed in comparison to a placebo or for healthy individuals.

This study will test the effectiveness of Engage & Connect, a 9-week remotely delivered psychotherapy for postpartum depression that focuses on reducing social isolation and helping mothers engage in more pleasurable activities.

Participants will be randomized to one of two groups, each consisting of 9 weekly therapy sessions. Randomization is like flipping a coin and there is a 50/50 chance of being assigned to either group.

Atypical choroid plexus papilloma (ACPP) and choroid plexus carcinoma (CPC) are both primary brain tumors that begin near the brain tissue. Choroid plexus carcinoma is fast-growing high-grade tumor, whereas atypical choroid plexus papilloma is an intermediate-grade tumor.

Removing these tumors through surgery has the best outcome for patients with ACPP or CPC, but there are often complications that can occur during the surgery. 

This is a clinical trial for adults with advanced solid tumors that have continued to grow despite the treatments already received.